𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PO27 Hematologic and cytogenetic response to imatinib mesylate in chronic myeloid leukemia

✍ Scribed by G. Narayanan; D.J. Chacko; A.A. Koshy; L. Soman

Book ID
114339890
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
43 KB
Volume
82
Category
Article
ISSN
1040-8428

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Acute myeloid leukemia developing during
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been